

CURRICULUM VITAE

Name: Ong Tee Chuan
Date of birth: 21st December 1971
Place of birth: Kuala Terengganu, Terengganu, Malaysia.
Marital status: Married
Sex: Male
Qualification: 1. MBBS (Universiti Malaya) 1996
2. MRCP (UK) 2000

Working Experience:

1. House officer in Hospital Pulau Pinang, Pulau Pinang, Malaysia (June 1996 to June 1997)
2. Medical officer:
 - a) Hospital Sik, Kedah – District hospital (June 1997 to May 1998)
 - b) Department of Medicine, Hospital Alor Setar, Kedah (May 1998 to October 2000)
3. Clinical specialist:
 - a) General Internal Medicine, Hospital Alor Setar, Kedah (October 2000 to May 2001)
 - b) General Internal Medicine, Hospital Umum Sarawak, Kuching, Sarawak (May 2001 to March 2003)
 - c) Haematology Department, Hospital Kuala Lumpur (March 2003 to October 2005)
4. Attachment in Allogeneic Stem Cell Transplantation:
 - a) Stem Cell Transplantation Centre, University Hospital, Wuerzburg, Germany (October 2005 to August 2006)
5. Consultant in Clinical Haematology :
 - a) Hospital Sultanah Aminah, Johor Bahru (Since September 2006 – December 2007)
 - b) Hospital Ampang, Selangor (January 2008 until now)
6. Head of Clinical Research Centre in Hospital Ampang from 2008 until Oct 2010.

Membership:

A life member of

- Malaysian Society of Haematology (MSH)
- Malaysian Society of Transplantation
- Postgraduate Society of Haematology Malaysia (PoSH)

An ordinary member of

- European Hematology Association (EHA)
- The Max Family Malaysia (cancer patient support group)

Publications:

1. A. Younes, A. Sureda, D. Ben-Yehuda, T.C. Ong, D. Tan, A. Engert, C. Le Corre, J. Gallagher, S. Hirawat, M. Prince. Phase 2 study of oral Panobinostat in patients with relapsed/refractory Hodgkin Lymphoma after high dose chemotherapy with autologous stem cell transplant. **Haematologica** 2009; 94 (Suppl 2): 34
2. Tan TC, Ong TC, Wong SP, Chang KM. AUDIT OF THE SAFETY AND EFFICACY OF ARSENIC TRIOXIDE USED IN HOSPITAL AMPANG FROM JULY 2006 - JULY 2009. **Journal of Health Management**
3. Jew Win Kuan, KianMeng Chang, Ngee Siang Lau, Purushothaman Visalachy, Sen Mui Tan, Tee Chuan Ong, Anselm Ting Su. The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. *Indian Journal of Hematology and Blood Transfusion*. September 2011, Volume 27, Issue 3: 136-145
4. Anas Younes, Anna Sureda, Dina Ben-Yehuda, Pier Luigi Zinzani, Tee Chuan Ong, H. Miles Prince, Simon J.Harrison, Mark Kirchbaum, Patrick Johnston, Jennifer Gallagher, Christophe Le Corre, Angela Shen, Andreas Engert. Panobinostat in Patients With Relapsed/Refractory Hodgkin Lymphoma Patients After Autologous Stem Cell Transplant: Results of a Phase II Study. **Journal of Clinical Oncology** June 20, 2012: 2197-2203
5. Sujatha Suthandiram, Gin Gin Gan, Shamsul Mohd Zain, Batoul Sadat Haerian, Ping Chong Bee, Lay Hoong Lian, Kian Meng Chang, Tee Chuan Ong, Zahurin Mohamed. **Polymorphisms in methylenetetrahydrofolate reductase gene and risk of non-Hodgkin lymphoma in a multi-ethnic population**. *J Hum Genet* 2014 May 20;59(5):280-7.
6. Sujatha Suthandiram, Gin-Gin Gan, Shamsul Mohd Zain, Ping-Chong Bee, Lay-Hoong Lian, Kian-Meng Chang, Tee-Chuan Ong, Zahurin Mohamed. **Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies**. *Pharmacogenomics* 2014 Aug;15(11):1479-94.
7. Lam Kah Yuen, Zakaria Zubaidah, Ivyna Bong Pau Ni, Megat Baharuddin Puteri Jamilatul Noor, Esa Ezalia, Chin Yuet Meng, Ong Tee Chuan, Vegappan Subramanian, Chang Kiang Meng. **High-Resolution Analysis of Chromosomal Alterations in Adult Acute Lymphoblastic Leukemia**. *Journal of Hematology*, Volume 3, Number 3, September 2014, pages 65-71.
8. Yat-Yuen Lim, Yoon-Ming Chin, Mei-Chee Tai, Somayeh Fani, Kian-Meng Chang, Tee-Chuan Ong, Ping-Chong Bee, Gin-Gin Gan, Ching-Ching Ng.

- Analysis of interleukin-10 promoter single nucleotide polymorphisms and risk of non-Hodgkin lymphoma in a Malaysian population.** *Leuk Lymphoma* 2015 Jan 6;56(1):163-8.
9. Suthandiram S, Gan GG, Zain SM, Bee PC, Lian LH, Chang KM, Ong TC, Mohamed Z. **Genetic polymorphisms in the one-carbon metabolism pathway genes and susceptibility to non-Hodgkin lymphoma.** *Tumour Biol.* 2015 Mar;36(3):1819-34
 10. Jew-Win Kuan, Anselm-Ting Su, Shu-Ping Wong, Xavier Yoon-Han Sim, See-Guan Toh, Tee-Chuan Ong, Jay-Suria Rajasuriarr, Su-Hong Lim, Yong-Khee Guan, Hong-Keng Liew, Pek-Kuen Liew, Jerome Tsen-Chuen Tan, Ahlam-Naila Kori, Yui-Yin Cheng, Sen-Mui Tan, Kian-Meng Chang. **A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.** *Transfus Apher Sci* 2015 Oct 30;53(2):196-204. Epub 2015 Mar 30.
 11. Hughes, TP, Munhoz, E, Aurelio Salvino, M, Ong, TC, Elhaddad, A, Shortt, J, Quach, H, Pavlovsky, C, Louw, VJ, Shih, L-Y, Turkina, AG, Meillon, L, Jin, Y, Acharya, S, Dalal, D & Lipton, JH 2017, '**Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: Final results from ENESTxtnd**' *British Journal of Haematology*. DOI: 10.1111/bjh.14829.

Writing:

Poster presentation:

1. Engraftment Characteristics and Incidence of Acute & Chronic Graft-versus-host disease (GVHD) using G-CSF-stimulated Marrow for Allogenic Matched Stem Cell Transplantation in a Multi-Ethnic Population.
8th Congress of the Asian Society of Transplantation (8th CAST) 2003
2. Peripheral stem cell mobilization – HKL experience
5th Malaysian National Haematology Scientific Meeting 2004
3. Case Report: The Use of Recombinant Factor VIIa in a Patient with Glazmann's Thrombasthenia
5th Malaysian National Haematology Scientific Meeting 2004
4. Myeloproliferative Disorder: A Ten-Year Experience In Hospital Kuala Lumpur
5th Malaysian National Haematology Scientific Meeting 2004
5. Case Report: Cyclosporin-induced Cortical Blindness
5th Malaysian National Haematology Scientific Meeting 2004
6. FLAG-IDA in the treatment of high risk Acute Myeloid Leukaemia
5th Ministry of Health Malaysia – Academy of Medicine of Malaysia Scientific Meeting 2004
7. Treatment of APML with AIDA regimen – update on Malaysian experience
6th Malaysian National Haematology Scientific Meeting 2006
8. Phase II study of oral Panobinostat in relapsed/refractory Hodgkin Lymphoma patients following AutoHSCT
EHA 2009
9. Phase II study of oral Panobinostat in relapsed/refractory Hodgkin Lymphoma patients following AutoHSCT
ASH 2010

10. Use of Rituximab in steroid refractory cGVHD in alloSCT patients *EBMT 2011*
11. Quality of life of patients with haematological malignancies or disorders before and after haematopoietic stem cell transplant , *EBMT 2011*
12. Yong Khee Guan, Tee Chuan Ong, Kian Meng Chang, Muhd Zanapiah Zakaria. Fludarabine-Cytarabine-Melphalan combination as high dose chemotherapy conditioning regime with autologous peripheral blood stem cell rescue. (Poster presentation for European Bone and Marrow Transplantation Meeting 2012).

Abstract:

1. Engraftment characteristics and Incidence of graft-versus-host disease using G-CSF stimulated marrow for allogeneic stem cell transplant
30th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2004
2. Ethnic difference in the incidence and severity of graft-versus-host disease in Malaysia
30th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2004
3. The use of STI 571 as pre-emptive therapy following stem cell transplant in 2 high-risk patients with refractory Ph positive ALL and CML myeloid blast crisis
31th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2005
4. The role of fludarabine, cytarabine, idarubicin and granulocyte-colony stimulating factor as salvage treatment before or after haematopoietic stem cell transplant
31th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2005
5. Outcome of patients with CML/Philadelphia chromosome positive ALL who received STI 571 (imatinib mesylate) before or after allogeneic stem cell transplant- a single centre experience
31th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2005
6. A. Younes, A. Sureda, D. Ben-Yehuda, T.C. Ong, D. Tan, A. Engert, C. Le Corre, J. Gallagher, S. Hirawat, M. Prince. Phase 2 study of oral Panobinostat in patients with relapsed/refractory Hodgkin Lymphoma after high dose chemotherapy with autologous stem cell transplant. **Haematologica** 2009; 94 (Suppl 2): 34

Oral Presentation:

1. Presenter in Haematology Update in Kuching, Sarawak, January, 2005 with topic on
 - a) Multiple Myeloma

- b) Aplastic Anemia
 - c) Emergencies in Haematology
2. Hospital CME on
 1. Multiple Myeloma
 2. Acute Promyelocytic Leukemia
 3. Immune thrombocytopenic purpura
 3. Speaker for Malaysian Society of Pharmacist in 2005 workshop in Oncology, with topic on “Non-Hodgkin’s Lymphoma – Changing the paradigm of treatment”
 4. Speaker for Sarawak Thalassaemia Camp December 2006 with topic on “Adult Thalassaemics – challenges faced”.
 5. Speaker for joint HSA/JSH/Puteri Specialist/Johor MMA monthly CME in March 2007 with topic on “Chronic Myeloid Leukemia”.
 6. Speaker for Malaysian Society of Transplantation Annual Scientific Meeting 2009
 7. Speaker for Malaysian Society of Haematology Annual Scientific Meeting 2011

Clinical Research:

1. Principle investigator (Hospital Ampang) for An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma
2. Principle investigator (Hospital Ampang) for A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
3. Principle investigator (Hospital Ampang) for An open-label, multicenter, expanded access study of oral AMN 107 in adult patients with Imatinib (Glivec®/Gleevec®) resistant or - intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase
4. Principle investigator (Hospital Ampang) for PROTOCOL ML18223 (NHL 13) A Multicentre, randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Aggressive B-cell
5. Principle investigator (Hospital Ampang) for A phase II study of oral Panobinostat in adult patients with relapsed/refractory classical Hodgkin's Lymphoma after failure of high-dose chemotherapy with autologous stem cell transfusion and a Gemcitabine- or Vinorelbine- or Vinblastine-containing treatment regimen
6. Co-Investigator of Malaysian National cancer Patient Registry for Haematology Malignancies
7. Principle investigator (Hospital Ampang) for An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma (VANTAGE trial)
8. Co-Investigator for LYM-2034 – A randomized, open lable, multicentre phase 2 study of combination of VR-CAP vs R-CHOP in subjects with newly diagnosed Non-Germinal Centre B cell subtype of Diffuse B Cell Lymphoma.
9. Co-Investigator for CNTO 328 – Anti-IL6 antibody for multicentric Castleman’s Disease.

10. Co-Investigator for GP13-301, a randomized, controlled, double blind phase III trial to compare efficacy, safety and pharmacokinetics of GP2013+CVP verses Rituximab-CVP for newly diagnosed Follicular Lymphoma.
11. Principle Investigator for ENESTxtnd – Extending molecular response with nilotinib in newly diagnosed CML.

Other:

1. Head of Clinical Research Unit, Hospital Ampang (2008 until October 2010)
2. Coordinator for ISO 9001 certification for Hospital Kuala Lumpur year 2004
3. Coordinator for accreditation of Hospital Kuala Lumpur year 2005
4. Member of Hospital Quality Assurance study on Unscheduled out-patient visits at specialized clinics year 2005
5. Design and maintain Electronic Prescription and Management of Chemotherapy for Clinicians and Pharmacist, Hospital Ampang since 2011.